The transcriptional response of human macrophages to murabutide reflects a spectrum of biological effects for the synthetic immunomodulator
- 14 June 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 128 (3) , 474-482
- https://doi.org/10.1046/j.1365-2249.2002.01872.x
Abstract
The synthetic immunomodulator murabutide (MB) presents multiple biological activities with minimal toxicity in animals and in man. Although MB is known to target cells of the reticuloendothelial system and to regulate cytokine synthesis, the molecular mechanisms underlying several of its biological effects are still largely unknown. In an effort to define cellular factors implicated in the immunomodulatory and HIV-suppressive activities of MB, we have undertaken profiling the regulated expression of genes in human monocyte-derived macrophages (MDM) following a 6-h stimulation with this synthetic glycopeptide. Oligonucleotide microarray analysis was performed on RNA samples of differentiated MDM from four separate donors, using probe sets corresponding to 1081 genes. We have identified, in a reproducible fashion, the enhanced expression of 40 genes and the inhibition of 16 others in MB-treated MDM. These regulated genes belonged to different families of immune mediators or their receptors, transcription factors and kinases, matrix proteins and their inhibitors, ion channels and transporters, and proteins involved in cell metabolic pathways. Additional verification of the regulated expression of selected genes was carried out using Northern blots or the quantification of released proteins in MDM cultures. The profile of MB-regulated genes in MDM provides a molecular basis for some of its previously reported biological activities, and reveals new set of genes targeted by the immunomodulator suggesting potential application in novel therapeutic indications.Keywords
This publication has 49 references indexed in Scilit:
- Clinical Tolerance and Profile of Cytokine Induction in Healthy Volunteers Following the Simultaneous Administration of IFN-αand the Synthetic Immunomodulator MurabutideJournal of Interferon & Cytokine Research, 2001
- Selective Regulation of Human Immunodeficiency Virus-Infected CD4+Lymphocytes by a Synthetic Immunomodulator Leads to Potent Virus Suppression In Vitro and in hu-PBL-SCID MiceJournal of Virology, 2001
- Drug target validation and identification of secondary drug target effects using DNA microarraysNature Medicine, 1998
- SELECTIVE POTENTIATION OF CYTOKINE EXPRESSION IN HUMAN WHOLE BLOOD BY MURABUTIDE, A MURAMYL DIPEPTIDE ANALOGUECytokine, 1996
- EnhancementIn Vivoof the Antiinflammatory and Antitumor Activities of Type I Interferon by Association with the Synthetic Immunomodulator MurabutideJournal of Interferon & Cytokine Research, 1996
- Enhancement by muramyl peptides of the protective response of interferon-α/β against encephalomyocarditis virus infectionInternational Journal of Immunopharmacology, 1996
- Synergistic Effects Between Recombinant Interleukin-2 and the Synthetic Immunomodulator Murabutide: Selective Enhancement of Cytokine Release and Potentiation of Antitumor ActivityJournal of Interferon & Cytokine Research, 1996
- Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutideInternational Journal of Immunopharmacology, 1995
- Role of glucose in interleukin‐1β production by lipopolysaccharide‐activated human monocytesJournal of Cellular Physiology, 1993
- Muramyl Peptides as Paradigms in NeuroimmunomodulationAnnals of the New York Academy of Sciences, 1992